The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.

Public Health Relevance

All of the research in the Experimental Therapeutics Program (ETP) has direct cancer relevance, Research objectives of Program investigators are directed toward the Identification of novel therapeutic agents and approaches for the treatment of cancer and translating these new cancer medicines in the clinic. To maximize ultimate clinical Impact, the ETP serves as a critical link between the basic science and clinical programs to enable the development of personalized therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-26
Application #
8696604
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
26
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396
Hertz, Daniel L; Kidwell, Kelley M; Vangipuram, Kiran et al. (2018) Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res 24:3602-3610
Parsels, Leslie A; Karnak, David; Parsels, Joshua D et al. (2018) PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res 16:222-232
Menghrajani, Kamal; Boonstra, Philip S; Mercer, Jessica A et al. (2018) Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma :1-7
Xiong, Xiufang; Liu, Xia; Li, Haomin et al. (2018) Ribosomal protein S27-like regulates autophagy via the ?-TrCP-DEPTOR-mTORC1 axis. Cell Death Dis 9:1131

Showing the most recent 10 out of 1493 publications